TECHNODERMA MEDICINES
Updated 6 days ago
No. 1, 14th Fl., Tower F2, Chengdu Tianfu BioPark, Sichuan, China
The com pany's current core research and development programs include innovative drugs for the treatment of androgenic alopecia, eczema/atopic dermatitis, psoriasis and lupus. TDM-105795, the world's leading small-molecule drug candidate for the treatment of androgenic alopecia, has now completed 2a clinical trials. TDM-180935, a novel JAK1/TYK2 inhibitor for eczema/atopic dermatitis, has also completed a Phase 1 clinical trial in December 2023 with favorable safety results, and Phase 2 a POC clinical trials are underway in the United States.
Also known as: TechnoDerma Medicines Inc.
Associated domains: rediandv.cn